HSP90AA1 and cancer: Furthermore, the fact that healthy cells are presumably more dependent on the tricarboxylic acid cycle—and therefore IDH3—than cancer cells might contribute to a narrowing of the therapeutic window for HSP90 inhibitors in vivo.